Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial

Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial

© 2016 Elsevier Ltd Background Venous thromboembolism occurs commonly in patients with cancer. Direct oral anticoagulants are non-inferior to conventional anticoagulants for the treatment of venous thromboembolism. We hypothesised that edoxaban, a direct oral inhibitor of activated clotting factor X...

Full description

Saved in:
Bibliographic Details
Main Authors: Gary E. Raskob, Nick van Es, Annelise Segers, Pantep Angchaisuksiri, Doyeun Oh, Zoltan Boda, Roger M. Lyons, Karina Meijer, Ivan Gudz, Jeffrey I. Weitz, George Zhang, Hans Lanz, Michele F. Mercuri, Harry R. Büller
Other Authors: University of Oklahoma Health Sciences Center
Format: Article
Published: 2018
Subjects:
Medicine
Online Access:https://repository.li.mahidol.ac.th/handle/123456789/41284
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Mahidol University

Internet

https://repository.li.mahidol.ac.th/handle/123456789/41284

Similar Items